Cellectis S.A. (CLLS)
Nasdaq: CLLS · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2014
Who owns Cellectis S.A.
As filed with the SECHolders of 5% or more
2
AstraZeneca PLC holds 44% of Ordinary shares, nominal value of EUR0.05 per ordinary share, as its SCHEDULE 13D/A filed Jan 24, 2025 says.
Directors and officers
0
report now, of 0 people on the record since . Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
AstraZeneca PLC
SCHEDULE 13D/A · filed Jan 24, 2025 · Ordinary shares, nominal value of EUR0.05 per ordinary share
Caisse des Depots
SCHEDULE 13D/A · filed Dec 12, 2025 · Ordinary Shares, nominal value EUR0.05 per share · 13.1% in Jan 30, 2025
What CLLS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Calyxt Inc
An entity · subsidiary · owns, named in the 20-F filed Mar 20, 2026
Cellectis Inc
An entity · legal entity · owns, named in the 20-F filed Mar 20, 2026
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.